10-Q: Intensity Therapeutics Reports Q3 Loss, Pauses Trials Amid Funding Challenges

Intensity Therapeutics reported a reduced net loss for the nine months ended September 30, 2025, but paused two key clinical trials due to funding constraints and dosing regimen revisions, while raising additional capital to extend its cash runway.

Summary

• Net loss for the nine months ended September 30, 2025, was $8.6 million, an improvement from $13.1 million for the same period in 2024.
• Research and development expenses decreased by $3.2 million (38%) to $5.3 million for the nine months ended September 30, 2025, primarily due to paused clinical trials and no manufacturing batches.
• General and administrative expenses decreased by $1.3 million (27%) to $3.5 million for the nine months ended September 30, 2025, due to reduced bonus accruals, lower insurance costs, and cost-saving initiatives.
• Cash and cash equivalents increased to $7.1 million as of September 30, 2025, from $2.6 million at December 31, 2024, largely due to equity financings.
• The INVINCIBLE-3 Study (Phase 3 Sarcoma) was paused for new site activations and patient enrollments in March 2025 due to funding constraints, with 21 patients enrolled prior to the pause.
• The INVINCIBLE-4 Study (Phase 2 Triple-Negative Breast Cancer) paused new patient enrollment in September 2025 to revise the dosing regimen due to localized skin irritation.
• The company believes it has sufficient cash to fund operations until the end of the first quarter of 2027, including $2.0 million net from an ATM offering and $4.0 million gross from an October 2025 Registered Direct Offering.
• The company has an accumulated deficit of $75.3 million as of September 30, 2025, and has raised substantial doubt about its ability to continue as a going concern.
• Common stock outstanding increased significantly to 49,068,621 shares as of September 30, 2025, from 15,122,873 shares at December 31, 2024, reflecting substantial dilution from equity raises.

Sentiment

Score: 3

Explanation: While the net loss decreased and cash position improved due to capital raises, the significant operational setbacks (pausing two key clinical trials due to funding and dosing issues), the explicit 'going concern' doubt, and Nasdaq compliance issues indicate a highly challenging period for the company. The dilution from capital raises is also substantial. The positive clinical data from INVINCIBLE-2 is overshadowed by these immediate concerns.

Positives

• Net loss significantly decreased to $8.6 million for the nine months ended September 30, 2025, from $13.1 million in the prior year period.
• Loss per share improved to $(0.33) for the nine months ended September 30, 2025, compared to $(0.95) for the same period in 2024.
• Cash and cash equivalents increased to $7.1 million as of September 30, 2025, from $2.6 million at December 31, 2024, bolstered by recent capital raises.
• The INVINCIBLE-2 Study demonstrated a high order of necrosis in presurgical breast cancer tumors, with some patients experiencing greater than 95% necrosis, and a favorable safety profile.
• The company successfully developed Phase 3 quality analytical methods for INT230-6 components and manufactured multiple large-scale batches.
• An agreed-upon CMC plan with the FDA for Phase 3 and product registration for INT230-6's ingredients is in place, with work anticipated to begin in Q4 2025.
• The company regained compliance with Nasdaq's minimum stockholders equity requirement as of August 8, 2025.

Negatives

• The INVINCIBLE-3 Study (Phase 3 Sarcoma) was paused for new site activations and patient enrollments in March 2025 due to funding constraints.
• The INVINCIBLE-4 Study (Phase 2 Triple-Negative Breast Cancer) paused new patient enrollment in September 2025 to revise the dosing regimen due to localized skin irritation.
• The company has an accumulated deficit of $75.3 million as of September 30, 2025.
• Management has raised substantial doubt about the company's ability to continue as a going concern.
• The company is not in compliance with Nasdaq's $1.00 minimum bid price requirement and has until December 3, 2025, to regain compliance.
• Significant dilution occurred due to multiple equity offerings, with common stock outstanding increasing from 15,122,873 shares at December 31, 2024, to 49,068,621 shares at September 30, 2025.
• No current year bonus accruals were made due to insufficient cash reserves and the assessment that payments are not reasonably probable.

Risks

• The company needs to raise additional funding to complete clinical trials and generate revenue from product sales.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may not be able to obtain regulatory approval for its product candidates.
• Failure to raise additional funds could lead to delays, reductions, or termination of research and product development.
• The ownership interest of existing stockholders may be diluted by future equity or convertible debt financings.
• The company may not satisfy Nasdaq Capital Market requirements for continued listing, specifically the $1.00 minimum bid price, which could result in delisting.
• Military actions in Russia and Israel could impact the company's ability to maintain and protect its patents in those regions.
• Changes to U.S. tariff and import/export regulations may have an adverse effect on the business.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future as it continues clinical development, manufacturing, and seeks regulatory approvals. It plans to restart INVINCIBLE-3 Study enrollment once sufficient funding is obtained and reinitiate INVINCIBLE-4 Study enrollment in Q1 2026 after a protocol amendment for dosing revision. The company anticipates initiating a small portion of CMC work in Q4 2025 and aims to complete INVINCIBLE-4 enrollment by the end of 2026, potentially adding resources.

Management Comments

• We expect to incur significant expenses and operating losses for the next several years as we continue to fund our INVINCIBLE-3 and INVINCIBLE-4 clinical studies, incur manufacturing costs, seek regulatory approvals, hire additional personnel, expand operational systems, invest in intellectual property, and establish commercial infrastructure.
• Our ability to ultimately generate revenue to achieve profitability will depend heavily on the development, approval, and subsequent commercialization of our product candidates.
• If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
• We will need substantial additional funding to support our continuing operations and pursue our growth strategy.
• If we fail to raise capital or enter into such agreements as and when needed, we would have to significantly delay, reduce, or eliminate the development and commercialization of one or more of our product candidates.
• Based on the cash and cash equivalents as of September 30, 2025, plus net proceeds received under the Company’s ATM Sales Agreement subsequent to September 30, 2025 and the October 2025 Registered Direct Offering, we believe that we have sufficient cash until the end of the first quarter of 2027 for our projected current operations.

Industry Context

Intensity Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on oncology with its DfuseRxSM platform and lead drug INT230-6. The challenges faced, such as significant operating losses, the need for continuous capital raises, and clinical trial pauses due to funding or dosing issues, are common for early to late-stage clinical-stage biopharmaceutical companies. The reliance on equity financing for operations and the inherent risks of regulatory approval and market acceptance are typical industry characteristics. The company's focus on intratumoral treatment for solid tumors addresses a significant unmet need, but successful commercialization requires overcoming substantial development and financial hurdles.

Comparison to Industry Standards

• The company's accumulated deficit of $75.3 million and consistent net losses are typical for a clinical-stage biotechnology company that has not yet brought a product to market.
• The need for continuous capital raises through equity offerings, leading to significant shareholder dilution, is a common financing strategy for biotech firms in the development phase, similar to many small-cap oncology developers.
• Pausing clinical trials due to funding constraints (INVINCIBLE-3) or the need for dosing regimen revisions (INVINCIBLE-4) are not uncommon in the complex and unpredictable landscape of drug development, though they represent significant setbacks.
• The positive necrosis data and favorable safety profile from the INVINCIBLE-2 Study in breast cancer are promising, but direct comparisons to specific competitor drugs or projects are not provided in the filing.
• The company's Nasdaq listing compliance issues (minimum bid price) are a common challenge for smaller public companies, especially those with significant R&D expenses and no revenue.

Related Party Transactions

• In October 2023, the company issued 80,000 warrants for consulting services to two shareholders, valued at $198,000, which were expensed over twelve months.
• In April 2024, the company entered into a non-material agreement with a service organization controlled by a board member, expensing $15,125 and paying $31,435 for services in the three months ended September 30, 2025, and expensing/paying $49,910 for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Significant dilution from recent and ongoing equity offerings. Potential for further dilution. Risk of delisting from Nasdaq could impact liquidity and valuation.
• Patients: Delays in clinical trials (INVINCIBLE-3 and INVINCIBLE-4) could impact access to potential treatments.
• Employees: No current year bonus accruals due to insufficient cash reserves, potentially impacting morale and retention.
• Creditors: The "going concern" doubt raises concerns about the company's long-term financial viability.
• Partners (Merck, BMS, Swiss Cancer Institute): Pauses in collaborative trials could affect timelines and outcomes of partnerships.

Next Steps

• Obtain sufficient funding to restart site activations and patient enrollment in the INVINCIBLE-3 Study.
• File a protocol amendment for the INVINCIBLE-4 Study dosing regimen in Q1 2026.
• Reinitiate enrollment for the INVINCIBLE-4 Study in Q1 2026, targeting completion by the end of 2026.
• Initiate a small portion of the agreed-upon CMC plan for Phase 3 and product registration in Q4 2025.
• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by December 3, 2025.
• Continue to raise additional capital through equity or debt financings to fund operations.

Key Dates

Recommendation

The company faces severe liquidity challenges, explicitly stating 'substantial doubt about its ability to continue as a going concern.' Two key clinical trials (Phase 3 Sarcoma and Phase 2 Triple-Negative Breast Cancer) are paused due to funding constraints and dosing issues, representing significant operational setbacks and delays in its core drug development. While recent capital raises extend the cash runway to Q1 2027, these have come at the cost of massive shareholder dilution, with common stock outstanding nearly tripling since year-end 2024. Furthermore, the company is non-compliant with Nasdaq's minimum bid price, risking delisting. Despite a reduced net loss, the underlying operational and financial instability, coupled with the high dilution and trial delays, presents a highly unfavorable investment profile. The risks far outweigh any potential upside from early-stage clinical data.

Keywords

Biotechnology, Oncology, Cancer Treatment, Clinical Trials, INT230-6, Sarcoma, Breast Cancer, Triple-Negative Breast Cancer, SEC Filing, Nasdaq Listing, DfuseRx, Immunotherapy, Drug Development, Capital Raise